This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.
Priyanka Yadav,
Ashish Kushwaha,
Arun Kumar Maurya,
Lalit Bisht,
Pratyush Purkayastha,
- Student, JBIT College of pharmacy, 23 Milestone, NH-07, Chakrata Rd, Shankarpur, Uttarakhand, India
- Assistant professor, JBIT College of pharmacy, 23 Milestone, NH-07, Chakrata Rd, Shankarpur, Uttarakhand, India
- Principal, JBIT College of pharmacy 23 Milestone, NH-07, Chakrata Rd, Shankarpur, Uttarakhand, India
- Vice Principal, 23 JBIT College of pharmacy Milestone, NH-07, Chakrata Rd, Shankarpur, Uttarakhand, India
- Assistant Professor, 23 JBIT College of pharmacy Milestone, NH-07, Chakrata Rd, Shankarpur, Uttarakhand, India
Abstract
Stable Ischemic Heart Disease (SIHD) is one of the leading cardiovascular disorders associated with high morbidity and mortality worldwide. Since early symptoms such as chest pain, fatigue, and shortness of breath are often non-specific and difficult to recognize, diagnosis becomes challenging, and many cases remain undetected until advanced stages or complications occur. Traditional diagnosis depends heavily on clinical evaluation, electrocardiography, stress testing, and imaging techniques. The development of improved treatment modalities, beyond conventional pharmacotherapy and revascularization strategies, remains an unmet medical need. Despite extensive research, there is still an urgent need to identify more disease-specific biomarkers that could further improve patient classification and therapeutic outcomes. A paradigm shift has been observed in SIHD research with advancements toward a better understanding of disease mechanisms, aiming for effective screening, early diagnosis, and personalized treatment strategies. This shift has been driven by innovations in genomics, proteomics, and advanced cardiovascular imaging technologies. Recent advances in molecular profiling and biomarker-driven strategies have significantly improved SIHD management. Noninvasive diagnostic techniques and digital health technologies have further enhanced early detection and risk stratification. This review aims to examine the evolving landscape of personalized therapies in SIHD, highlighting key biological targets, emerging therapeutic strategies, and future perspectives.
Keywords: Stable Ischemic Heart Disease, Personalized medicine, Biomarkers, Early diagnosis, Molecular profiling, Precision therapy.
References
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European heart journal. 2020 Jan 14;41(3):407-77. 2. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-119. 3. Joseph J, Velasco A, Hage FG, Reyes E. Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. Journal of Nuclear Cardiology. 2018 Apr 1;25(2):509-15. 4. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AH, Prescott E, Karam N, Appelman Y, Fraccaro C, Louise Buchanan G. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European heart journal. 2020 Oct 1;41(37):3504-20. 5. Crea F. The Atlas of cardiovascular disease in Europe and a focus on frailty and cardiovascular risk. European heart journal. 2022 Feb 21;43(8):703-5. 6. Gurbel PA, Tantry US. Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012 Mar 13;125(10):1276-87. 7. Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD. 2021 ACC/AHA/SCAT guideline for coronary artery revascularization. Journal of the American College of Cardiology. 2022 Jan 18;79(2):E21-129. 8. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD. Initial invasive or conservative strategy for stable coronary disease. New England Journal of Medicine. 2020 Apr 9;382(15):1395-407. 9. Leong DP, Yusuf R, Iqbal R, Avezum Á, Yusufali A, Rosengren A, Chifamba J, Lanas F, Diaz ML, Miranda JJ, Davletov K. The burden of cardiovascular events according to cardiovascular risk profile in adults from high-income, middle-income, and low-income countries (PURE): a cohort study. The Lancet Global Health. 2025 Aug 1;13(8):e1406-14. 10. Asrina A. Precision medicine approaches in oncology: current trends and future directions. Advances in Healthcare Research. 2024 Feb 28;2(1):36-48. 11. Collins FS, Varmus H. A new initiative on precision medicine. New England journal of medicine. 2015 Feb 26;372(9):793-5. 12. Hampel H, O’Bryant SE, Durrleman S, Younesi E, Rojkova K, Escott-Price V, Corvol JC, Broich K, Dubois B, Lista S, Alzheimer Precision Medicine Initiative. A precision medicine initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric. 2017 Mar 4;20(2):107-18.
Emerging Trends in Personalized Medicines
| Volume | 03 | |
| 02 | ||
| Received | 18/04/2026 | |
| Accepted | 31/05/2026 | |
| Published | 10/06/2026 | |
| Publication Time | 53 Days |